Influenza is an acute viral respiratory infectious disease caused by influenza viruses (types A, B, C, and rarely D) that triggers robust innate immunity and adaptive immunity responses. In cPNI context, influenza is paradigmatic for studying the critical importance of inflammatory resolution—severe outcomes often reflect failure to switch from pathogen clearance to tissue repair, not merely viral burden. The virus demonstrates how Specialized pro-resolving mediators (SPMs) determine whether an immune system response protects or destroys.
Imagine a house fire where the fire brigade (immune system) arrives to extinguish the flames (virus). The initial response is aggressive: firefighters smash windows (neutrophils and inflammatory cytokines), flood rooms with water (IFN-alpha, IL-6), and tear down walls to access hidden embers. This is necessary—the fire must be stopped. But if the firefighters never switch from "destroy mode" to "rebuild mode," the house becomes uninhabitable even though the fire is out. This is the cytokine storm: the rescue becomes the catastrophe.
Now picture a second crew arriving—the cleanup and reconstruction team (Resolvins, Protectins, Maresins). They tell firefighters to stop spraying water, clear debris, patch holes, and restore the structure. Without this second crew, you'd have charred ruins even though no flames remain. In severe influenza, this cleanup crew either never arrives or arrives too late—the virus is cleared but the lung tissue is destroyed by unresolved inflammation. The omega-3 fatty acids from your diet are the raw materials for building this cleanup crew.
¶ Viral Entry and Initial Recognition
Influenza virus enters respiratory epithelial cells via hemagglutinin binding to sialic acid receptors → viral RNA recognized by TLR3 and RIG-I-like receptors → activation of IRF5 and NF-kB → rapid transcription of type I interferon genes (IFN-α, IFN-β) within 2-4 hours of infection.
IFN-alpha release → autocrine/paracrine signaling via IFNAR1/2 receptors → JAK-STAT1/2 phosphorylation → expression of >300 interferon-stimulated genes (ISGs) → antiviral state in neighboring cells (viral replication inhibition, apoptosis sensitization).
Simultaneously: infected epithelial cells release IL-1, IL-6, TNF-α, IL-8 → recruitment of neutrophils (peak 24-48h), monocytes, NK cells → neutrophil degranulation and NETosis → collateral tissue damage → alveolar-capillary barrier breakdown → ARDS risk if unchecked.
IL-6 → hepatic acute phase response → CRP, serum amyloid A, ferritin elevation → neutrophil priming → TNF-α synergy → endothelial activation → vascular leak → pulmonary edema.
IL-1β (from NLRP3 inflammasome activation) → hypothalamic effects → fever, sickness behaviour, anorexia → metabolic redirection toward immune system (selfish immune system prioritization).
Early phase (0-48h): COX-2 and 5-LOX produce pro-inflammatory eicosanoids → Prostaglandin E2, Leukotriene B4 → leukocyte recruitment and activation.
Resolution phase (48-96h, if successful): Lipid mediator class switching → 15-LOX and 12-LOX convert omega-3 fatty acids (DHA/EPA) → Resolvins, Protectins, Maresins:
- RvD1 (resolvin D1) binds ALX-FPR2 on neutrophils → stop recruitment, enhance apoptosis
- Protectin D1 (PD1/neuroprotectin D1) → inhibits TNF-α and IL-1β transcription, promotes efferocytosis
- MaR1 (maresin 1) → macrophage reprogramming from M1→M2, tissue repair initiation
CD8+ T cells recognize viral peptides on MHC-I → cytotoxic killing of infected cells (peak day 7-10) → viral clearance → antibodies (IgM→IgG class switch) provide long-term immunity.
graph TD
A[Influenza Virus Entry] --> B[TLR3/RIG-I Activation]
B --> C["IRF5 + NF-κB"]
C --> D["IFN-α/β Production"]
D --> E["JAK-STAT → ISGs"]
C --> F["IL-6, TNF-α, IL-1β"]
F --> G[Neutrophil/Monocyte Recruitment]
G --> H["NETosis + ROS Release"]
H --> I{Resolution Switch?}
I -->|"YES: SPM Production"| J["15-LOX → RvD1, PD1, MaR1"]
J --> K[Neutrophil Apoptosis]
J --> L[Efferocytosis by Macrophages]
J --> M["Tissue Repair + Homeostasis"]
I -->|"NO: Failed Switch"| N["Persistent IL-6/TNF-α"]
N --> O[Cytokine Storm]
O --> P[Alveolar Damage]
O --> Q[Vascular Leak]
P --> R[ARDS]
Q --> R
style I fill:#ff9,stroke:#333,stroke-width:4px
style J fill:#9f9,stroke:#333,stroke-width:2px
style O fill:#f99,stroke:#333,stroke-width:2px
In severe influenza (especially H1N1, H5N1): insufficient DHA tissue stores + overwhelmed 15-LOX capacity + persistent viral replication → SPM production fails → neutrophils continue infiltrating → NETosis-mediated DNA-histone complexes damage endothelium → microvascular thrombosis → lung compliance drops → hypoxemia → multi-organ failure.
Cytokine storm defined as: IL-6 >80 pg/mL, IL-1β >5 pg/mL, TNF-α >20 pg/mL, ferritin >500 ng/mL (often >3000 in severe cases).
Most influenza deaths are not from direct viral cytopathology but from immunopathology—the immune system destroys the lung while attempting rescue. Elderly patients and those with metabolic syndrome show impaired resolution capacity: lower tissue DHA levels, reduced 15-LOX expression, chronic low-grade inflammation that depletes SPM precursors. This explains why metabolic health predicts influenza outcomes more than viral load.
¶ Evolutionary Mismatch and Modern Vulnerabilities
Hunter-gatherer omega-3 fatty acids intake (~3g EPA+DHA/day) versus modern Western diet (~0.1-0.2g/day) = 15-30× reduction in SPM precursor availability. The immune system evolved expecting abundant marine-derived fats for resolution—modern diets create a "resolution deficit" that converts normally manageable infections into life-threatening events.
Influenza demonstrates intermittent living principles: the virus triggers acute stress requiring metabolic flexibility—shifting from anabolic (viral replication suppression via IFN-alpha-induced protein synthesis inhibition) to catabolic (fever-driven proteolysis, muscle wasting to fuel immune system). Sickness behaviour is adaptive: social withdrawal prevents transmission, sleep enhances resolution, appetite loss redirects energy to leukocytes (selfish immune system).
Pre-infection preparation:
- Omega-3 supplementation (2-4g EPA+DHA daily) for 4+ weeks increases tissue DHA stores → enhanced SPM synthesis capacity
- Adequate vitamin D (>30 ng/mL 25-OH-D) optimizes interferon responses without excessive inflammation
- Metabolic optimization: improve insulin sensitivity, reduce visceral adiposity → lower baseline IL-6, better leukocyte function
During acute infection:
- Continue omega-3s (some evidence for 6-8g/day acutely)
- Avoid premature antipyretics unless fever >39.5°C (fever enhances viral clearance and SPM enzyme activity)
- Support efferocytosis: adequate protein (1.2-1.5g/kg), vitamin C (1-2g), zinc (30mg)
- Monitor CRP and ferritin as proxies for resolution failure—rising values after day 5 suggest intervention need
Post-infection recovery:
- Active resolution support for 2-4 weeks: continued omega-3s, antioxidants (quercetin, curcumin)
- Graded return to activity—premature exertion can trigger inflammation relapse
- Address metabolic consequences: muscle protein refeeding, mitochondrial support (CoQ10, creatine)
- Worsening symptoms after day 5-7
- CRP >100 mg/L beyond day 3
- Ferritin >500 ng/mL (especially >1000)
- Persistent tachycardia (>100 bpm at rest)
- New onset confusion (cerebral microvascular inflammation)
→ These indicate cytokine storm risk, consider hospitalization, possible corticosteroids (but timing critical—steroids before viral clearance worsen outcomes)
Exogenous SPM administration (RvD1, AT-RvD1) shows promise in animal models: 50% reduction in lung pathology, improved survival without impairing viral clearance. Human trials pending, but mechanism suggests SPMs could be game-changing: they selectively terminate inflammation while preserving antimicrobial functions—the holy grail of infectious disease management.
- Influenza virus replicates every 6-8 hours; peak viral load occurs 48-72h post-infection
- Type I interferon response peaks 12-24h after infection, preceding symptom onset
- Neutrophil infiltration into lungs peaks day 2-3; if still elevated day 7+, predicts severe outcomes
- Protectin D1 (PD1) reduces influenza-induced lung inflammation by 50% in murine models without affecting viral titers
- Cytokine storm mortality in 1918 Spanish flu disproportionately killed healthy young adults (ages 20-40) due to robust immune responses exceeding resolution capacity
- Omega-3 index <4% (red blood cell EPA+DHA percentage) associates with 3× higher severe influenza risk versus >8%
- IL-6 trans-signaling (IL-6 + soluble IL-6 receptor) drives endothelial damage in ARDS—occurs when IL-6 >50 pg/mL
- Fever is pro-resolving: 38-39°C optimizes 15-LOX enzymatic activity for SPM production
- Ferritin >1000 ng/mL during influenza indicates macrophage activation syndrome risk
- Post-influenza fatigue can persist 2-8 weeks due to mitochondrial dysfunction from inflammatory oxidative stress
- H5N1 (avian flu) case fatality rate ~60% reflects extreme cytokine storm—IL-6 levels 100× higher than seasonal flu
- Aspirin (low-dose) during influenza may enhance AT-RvD1 production (aspirin-triggered resolvin), but evidence mixed—NSAIDs generally discouraged
- Specialized pro-resolving mediators (SPMs) — Essential for terminating influenza-induced inflammation; deficiency drives severe outcomes
- Resolvins — RvD1 and RvE1 specifically reduce neutrophil recruitment and promote macrophage-mediated debris clearance in influenza
- Protectins — Protectin D1/neuroprotectin D1 is most protective SPM in influenza, blocking NF-κB-driven cytokine transcription
- Maresins — MaR1 reprograms macrophages from inflammatory (M1) to reparative (M2) phenotype during viral clearance phase
- Lipid mediator class switching — The critical pivot from prostaglandin/leukotriene production to SPM synthesis determines influenza severity
- omega-3 fatty acids — EPA and DHA are obligate precursors for influenza-protective SPMs; tissue stores predict outcomes
- 15-LOX — Rate-limiting enzyme for resolvin and protectin synthesis from DHA during infection resolution
- Cytokine storm — Uncontrolled IL-6/TNF-α/IL-1β production when resolution mechanisms fail; primary cause of influenza mortality
- type I interferon — IFN-α/β provide early antiviral defense but must be tightly regulated; persistent production impairs resolution
- IL-6 — Dual role: necessary for early viral defense, pathological when trans-signaling persists beyond day 5-7
- TNF-α — Drives endothelial activation and vascular leak; SPMs directly inhibit TNF-α transcription
- neutrophils — Essential for early viral containment, but NETosis-mediated tissue damage requires SPM-triggered apoptosis and clearance
- NETosis — Neutrophil extracellular trap formation damages alveolar epithelium and endothelium in severe influenza
- efferocytosis — Macrophage clearance of apoptotic neutrophils; SPMs enhance this process, preventing secondary necrosis
- NLRP3 inflammasome — Activated by influenza viral proteins, driving IL-1β release; resolution phase requires inflammasome deactivation
- sickness behaviour — Adaptive behavioral changes (fatigue, social withdrawal, anorexia) orchestrated by IL-1β and prostaglandins
- selfish immune system — Immune prioritization during influenza diverts 20-30% of metabolic resources, causing muscle catabolism
- metabolic syndrome — Impairs both antiviral immunity and resolution capacity; visceral fat secretes anti-resolving mediators
- ARDS — Acute respiratory distress syndrome from failed inflammation resolution; alveolar-capillary barrier destruction
- chronic inflammation — Baseline inflammatory state depletes resolution capacity, explaining why chronic diseases worsen influenza
- innate immunity — TLR3/RIG-I viral recognition triggers type I interferon cascade; over-activation without resolution = pathology
- adaptive immunity — CD8+ T cells clear virus; antibodies prevent reinfection; requires resolved inflammation for proper memory formation
- COX-2 — Early enzyme producing PGE2 for inflammation; acetylated by aspirin to produce aspirin-triggered resolvins
- ferritin — Acute phase reactant; persistently elevated levels indicate macrophage activation and resolution failure
- acute phase response — Hepatic synthesis of CRP, SAA, hepcidin; adaptive short-term, pathological if prolonged
- DHA — Docosahexaenoic acid from fish/algae; converted to D-series resolvins and protectins via 15-LOX
- EPA — Eicosapentaenoic acid; precursor to E-series resolvins via 5-LOX and 12-LOX pathways